The Venture Codex Logo

The Venture Codex

Ascletis

1002 Northridge Ln, Chapel Hill, NC, United States

Overview

Global specialty therapeutics business for cancer and infectious diseases.

Founded

2011

Deals ยท 12mo

0

Links

WebsiteLinkedIn

Stage focus

Series E

Geographic focus

United States

Sector focus

Health Care
Medical
Therapeutics

Investment portfolio

3rounds
NAMEDATESIZE
Sagimet Biosciences
Feb 2021Participated
$80 MOther Equity
Sagimet Biosciences
Aug 2019Led
$7 MSeries E
Sagimet Biosciences
Feb 2019Led
$18 MSeries E
Sagimet Biosciences
Feb 2021Participated
$80 MOther Equity
Sagimet Biosciences
Aug 2019Led
$7 MSeries E
Sagimet Biosciences
Feb 2019Led
$18 MSeries E
3
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Ascletis: 3 funding rounds are recorded in the selected participation categories.All available history.
Ascletis: 3 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series C+20
Other Equity01

Monthly Deal Activity

Ascletis: 3 deals are recorded across 93 months.All available history.
Ascletis: 3 deals are recorded across 93 months. All available history
MonthDeals
Feb '191
Mar '190
Apr '190
May '190
Jun '190
Jul '190
Aug '191
Sep '190
Oct '190
Nov '190
Dec '190
Jan '200
Feb '200
Mar '200
Apr '200
May '200
Jun '200
Jul '200
Aug '200
Sep '200
Oct '200
Nov '200
Dec '200
Jan '210
Feb '211
Mar '210
Apr '210
May '210
Jun '210
Jul '210
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Ascletis: Health & Life Sciences is the largest displayed sector by deal count (3 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Ascletis: Health & Life Sciences is the largest displayed sector by deal count (3 deals). All available history
SectorDeals
Health & Life Sciences3

Deal Size Distribution

Ascletis: 3 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Ascletis: 3 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M1
$10M-$25M1
$25M-$50M0
$50M-$100M1
$100M-$250M0
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

Ascletis: United States has the largest recorded deal count among the displayed regions (3 deals).All available history.

Top 1 of 1 regions; European countries are grouped as Europe.

Ascletis: United States has the largest recorded deal count among the displayed regions (3 deals). All available history
RegionDeals
United States3
Ascletis: 9 co-investors are shown, with Kleiner Perkins sharing 3 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Ascletis: 9 co-investors are shown, with Kleiner Perkins sharing 3 recorded deals. All available history
Co-investorShared deals
Kleiner Perkins3
New Enterprise Associates3
Altium Capital1
HM Capital1
Invus1
PFM Health Sciences1
Qianhai Ark1
Qianhai Ark (Cayman) Investment1
Rock Springs Capital1

Investment Strategy

Ascletis: Led accounts for 67% and participating for 33% of round participation.All available history.
Ascletis: Led accounts for 67% and participating for 33% of round participation. All available history
CategoryDeals (count)Share (%)
Led267%
Participating133%
Ascletis: Single-lead accounts for 100% and co-led for 0% of lead dynamics.All available history.
Ascletis: Single-lead accounts for 100% and co-led for 0% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead2100%
Co-led00%

Team

Jinzi Wu

Founder & President , CEO

John P. Gargiulo

CBO

Judy Wu

Vice President

Vivian Chen

VP, Corporate Affairs

Yuemei Yan

VP, Sales